Derek Archila analyst WELLS FARGO

Currently out of the existing stock ratings of Derek Archila, 167 are a BUY (66.01%), 82 are a HOLD (32.41%), 4 are a SELL (1.58%).

Derek Archila

Work Performance Price Targets & Ratings Chart

Analyst Derek Archila, currently employed at WELLS FARGO, carries an average stock price target met ratio of 53.62% that have a potential upside of 43.01% achieved within 141 days.

Derek Archila’s has documented 491 price targets and ratings displayed on 45 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CABA, Cabaletta Bio at 01-Apr-2025.

Wall Street Analyst Derek Archila

Analyst best performing recommendations are on ARNA (ARENA PHARMACEUTICALS).
The best stock recommendation documented was for ARNA (ARENA PHARMACEUTICALS) at 12/10/2021. The price target of $71 was fulfilled within 3 days with a profit of $21.06 (42.17%) receiving and performance score of 140.57.

Average potential price target upside

AIMT Aimmune Therapeutics AMRN Amarin PLC ASND Ascendis Pharma AS CBAY Cymabay Therapeu IMVT Immunovant  KZR Kezar Life Sciences MNTA Momenta Pharmaceuticals PCRX Pacira Pharmaceuticals RYTM Rhythm Pharmaceuticals SGYP Synergy Pharmaceuticals VNDA Vanda Pharmaceuticals GLPG Galapagos NV ADR ICPT Intercept Pharmaceuticals NGM NGM Biopharmaceuticals PHAS PhaseBio Pharmaceuticals PRNB Principia Biopharma APLS Apellis Pharmaceuticals ARVN Arvinas CCCC C4 Therapeutics  HZNP Horizon Pharma PLC INCY yte KYMR Kymera Therapeutics NRIX Nurix Therapeutics  CABA Cabaletta Bio GLUE Monte Rosa Therapeutics MORF Morphic ARGX argenx NV ADR RXDX Prometheus Biosciences URGN UroGen Pharma Ltd ARNA Arena Pharmaceuticals BPMC Blueprint Medicines Corp ESPR Esperion Therapeutics HRTX Heron Therapeuti TEVA Teva Pharma Industries Ltd ADR ZYNE Zynerba Pharmaceuticals CLDX Celldex Therapeutics DICE Dice Molecules Holdings LLC MOR MorphoSys AG ADR VTYX Ventyx Biosciences ZNTL Zentalis Pharmaceuticals Llc ANAB AnaptysBio ANNX Annexon  EXEL Exelixis VRDN Viridian Therapeutics ZYME Zymeworks Common Stock

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$18

4 years 7 months 6 days ago
(01-Sep-2020)

3/3 (100%)

$3.19 (21.54%)

78

Hold

$60

4 years 7 months 7 days ago
(31-Aug-2020)

0/19 (0%)

$41.31 (221.03%)

Hold

$34.5

$0.01 (0.03%)

$66

4 years 7 months 7 days ago
(31-Aug-2020)

1/8 (12.5%)

$0.28 (0.82%)

39

Hold

$34.5

$0.01 (0.03%)

$14

4 years 7 months 7 days ago
(31-Aug-2020)

7/7 (100%)

$0.28 (0.82%)

105

Hold

$35

$0.51 (1.48%)

$24

4 years 7 months 7 days ago
(31-Aug-2020)

7/17 (41.18%)

$0.78 (2.28%)

376

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Derek Archila is most bullish on?

Potential upside of $185.89 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Derek Archila is most reserved on?

Potential downside of $1.43 has been obtained for EXEL (EXELIXIS)

What Year was the first public recommendation made by Derek Archila?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?